表紙:点頭てんかんの世界市場(2021年~2028年)
市場調査レポート
商品コード
1017415

点頭てんかんの世界市場(2021年~2028年)

Global Infantile Spasm Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
点頭てんかんの世界市場(2021年~2028年)
出版日: 2021年07月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

点頭てんかん市場の成長は、出生数の増加、点頭てんかんの有病率の上昇、製品の革新、点頭てんかんの治療における科学的進歩の高まりによって推進されています。

最近の技術の進歩により、発作を検知し、医師に警告する発作警告装置が考案されました。この技術の進歩により、医師による早期診断が可能となります。点頭てんかんを正確に診断することで、医師は適切な治療方法を紹介するための正確な判断ができ、治療の効率が向上します。さらに、これらの先端技術は、未診断の人口を減らすことにも役立つため、点頭てんかん治療薬の普及率の向上が期待されています。

ただし、点頭てんかん薬の高いコストは、市場成長を抑制する可能性があります。たとえば、Mallinckrodt Pharmaceuticalのコルチコトロピンブランド製品であるActharは、患者1人あたり約12万5,000米ドル、つまり1回の投与あたり2万8,000米ドルの費用がかかります。

当レポートは、世界の点頭てんかん市場について調査しており、市場規模、機会や影響、成長および抑制要因、COVID-19による影響、製品タイプ・投与経路・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 世界の点頭てんかん市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界の点頭てんかん市場-市場の定義と概要

第3章 世界の点頭てんかん市場-エグゼクティブサマリー

  • 製品タイプ別の市場内訳
  • 投与経路別の市場内訳
  • 流通チャネル別の市場内訳
  • 地域別の市場内訳

第4章 世界の点頭てんかん市場-市場力学

  • 市場に影響を与える要因
    • 成長要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の点頭てんかん市場-業界分析

  • ポーターのファイブフォース分析
  • PEST分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界の点頭てんかん市場-COVID-19分析

  • 市場でのCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在の市場シナリオ
    • COVID-19以後または今後のシナリオ
  • Covid-19における価格動向
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の点頭てんかん市場-製品タイプ別

  • イントロダクション
    • 市場規模分析および前年比成長分析
    • 市場魅力指数
  • 副腎皮質刺激ホルモン
  • ビガバトリン
  • フェーズIII

第8章 世界の点頭てんかん市場-投与経路別

  • イントロダクション
    • 市場規模分析および前年比成長分析
    • 市場魅力指数
  • 経口
  • 非経口

第9章 世界の点頭てんかん市場-流通チャネル別

  • イントロダクション
    • 市場規模分析および前年比成長分析
    • 市場魅力指数
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 世界の点頭てんかん市場-地域別

  • イントロダクション
    • 市場規模分析(2018-2028)、および前年比成長分析(2020-2028)
    • 市場魅力指数
  • 北米
    • イントロダクション
    • 主要地域別の力学
    • 製品タイプ別:市場規模分析、および前年比成長分析
    • タイプ別:市場規模分析、および前年比成長分析
    • 流通チャネル別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 欧州
    • イントロダクション
    • 主要地域別の力学
    • 製品タイプ別:市場規模分析、および前年比成長分析
    • タイプ別:市場規模分析、および前年比成長分析
    • 流通チャネル別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 南米
    • イントロダクション
    • 主要地域別の力学
    • 製品タイプ別:市場規模分析、および前年比成長分析
    • タイプ別:市場規模分析、および前年比成長分析
    • 流通チャネル別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • アジア太平洋
    • イントロダクション
    • 主要地域別の力学
    • 製品タイプ別:市場規模分析、および前年比成長分析
    • タイプ別:市場規模分析、および前年比成長分析
    • 流通チャネル別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 中東とアフリカ
    • イントロダクション
    • 主要地域別の力学
    • 製品タイプ別:市場規模分析、および前年比成長分析
    • タイプ別:市場規模分析、および前年比成長分析
    • 流通チャネル別:市場規模分析、および前年比成長分析

第11章 世界の点頭てんかん市場-競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業
  • 革新的技術を持つ企業
  • スタートアップ企業

第12章 世界の点頭てんかん市場-企業プロファイル概要

  • Mallinckrodt Pharmaceuticals
    • 企業概要
    • 製品ポートフォリオ・概要
    • 要点
    • 財務概要
  • Valerion Therapeutics
  • Anavex Life Sciences Corp
  • GW Pharmaceuticals, plc
  • H. Lundbeck A/S
  • ORPHELIA Pharma SA
  • INSYS Therapeutics, Inc
  • Retrophin, Inc
  • Catalyst Pharmaceuticals
  • Amneal Pharmaceuticals
  • QUALITY CONTROL CHEMICALS INC
  • BOC Sciences
  • Chongqing Chemdad Co., Ltd
  • Shanghai Longyu Biotechnology Co., Ltd
  • Dayang Chemicals Co., Ltd.

第13章 世界の点頭てんかん市場-DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH3524

Market Overview

The global infantile spasm market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Infantile spasm is also known as a West syndrome, is a rare seizure condition in an epilepsy syndrome of infancy and childhood. Infantile spasms are typically sudden, brief, bilateral and symmetric contractions of the muscles of the neck, trunk and extremities, occurring in clusters. Infantile spasms are often the presenting feature of a significant underlying neurological disorder.

Market Dynamics

The infantile spasm market growth is driven by the increasing number of births, rising prevalence of infantile spasms, product innovations, and growing scientific advancements in the treatment for infantile spasms.

Growing scientific advancements in the treatment for infantile spasms, is expected to drive the growth in the forecast period

The growing scientific advancements in the treatment of infantile spasms are driving the market growth. For example, due to recent advancements in the technology, a seizure alert device has been designed to detect seizures and warns the physician through phone calls, alarms, or text messages. This advancement aids in the early diagnosis by physicians, which increases the life expectancy of patients. The precise diagnosis of infantile spasms helps the physician make an accurate decision to refer an appropriate treatment procedure, thus improving the efficiency of the treatment. In addition, these advanced technologies also help reduce the undiagnosed population, thereby enhancing the penetration rate of infantile spasm drugs.

Rising prevalence of infantile spasms, is expected to drive the growth in the forecast period

According to the National Organization for Rare Disorders, the incidence of infantile spasms is 2 to 3 per 10,000 live births, with a lifetime prevalence of 1.5 to 2 per 10,000 children. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies in the first year of life. Almost 2,000-4,000 new cases are diagnosed in the U.S. annually. About 50%-70% of infantile spasms patients are affected by other types of seizures, whereas nearly 18%-50% develop either Lennox-Gastaut syndrome or other forms of symptomatic generalized epilepsy.

High cost of treatment is likely to hamper the market growth

The high cost of infantile spasm drugs may restrict market growth. For instance, Acthar, which is a corticotropin branded product from Mallinckrodt pharmaceutical, costs around US$ 125,000 per patient, i.e., US$ 28,000 per dose.

COVID-19 Impact Analysis

The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted major companies' financial status in the urea cycle disorders treatment market. The private healthcare sector is one of the sectors, which the COVID-19 pandemic has majorly impacted. The pandemic has negatively impacted the global infantile spasm market in various aspects such as research and development, production, and supply of medicines. The pandemic has also affected the growth of pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries.

Segment Analysis

The Adrenocorticotropic hormone segment is expected to hold largest share in this market segment

Adrenocorticotropic hormone therapy is the most commonly used for infantile spasms in the United States owing to low side effects and greater efficacy than other medications. ACTH reduces neuronal excitability in IS by two mechanisms of action: (1) by inducing steroid release and (2) by a direct, steroid-independent action on melanocortin receptors. These combined effects may explain the robust, established clinical effects of ACTH in the therapy of IS.

The oral segment is expected to hold largest share in this market segment

Oral routes have advantages like ease in administration and low cost. For instance, according to the National Library of Medicine, the more cost-effective treatment was high-dose prednisolone, with an incremental cost-effectiveness ratio (ICER) of $333 per case of spasms resolved, followed by ACTH ICER of $1 432 200 per case of spasms.

For instance, Bio-Pharm Solutions Co., Ltd developing an orally administered JBPOS0101 for refractory infantile spasms patients, is currently under Phase 2 trials is expected to complete by 2022. Moreover, Aucta Pharmaceuticals and Upsher-Smith Laboratories, LLC launched vigabatrin for oral solution under the brand name Vigadrone in July 2018, which is another generic version of vigabatrin (Sabril)

The hospital pharmacies segment is expected to hold largest share in this market segment

The hospital pharmacies held the largest share in the infantile spasm market. This is mainly owing to increasing number of patients suffering from conditions which are diagnosed, treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share of global infantile spasm market

The North American region holds a dominant position in the global infantile spasm market due to infantile spasms treatment procedures and large-scale research and development activities. For example, INSYS Therapeutics developed Cannabidiol in October 2012, Oral Solution for infantile spasm under phase III clinical trial. The increasing prevalence of central nervous system (CNS) infection can develop infantile spasms. For instance, in July 2012, the National Center for Biotechnology Information (NCBI) report stated that around 50% of infantile spasm cases in the U.S. have a prenatal cause, including central nervous system infection, intrauterine insults, neurologic disorders such as tuberous sclerosis complex (TSC), and genetic syndrome. Moreover, according to the Infantile Spasms Project, approximately 2000 to 4000 new cases of this disorder occur in the U.S. every year.

Furthermore, approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) that helps speedy approval by designating the orphan drug status to drugs targeted to benefit patients with a rare disease is expected to boost this region's market growth.

Competitive Landscape

The global infantile spasm market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Valerion Therapeutics, Anavex Life Sciences Corp., GW Pharmaceuticals, plc., Mallinckrodt, H. Lundbeck A/S, ORPHELIA Pharma SA, INSYS Therapeutics, Inc., Retrophin, Inc., and Catalyst Pharmaceuticals, Amneal Pharmaceuticals, QUALITY CONTROL CHEMICALS INC, BOC Sciences, Chongqing Chemdad Co., Ltd, Shanghai Longyu Biotechnology Co., Ltd, Dayang Chemicals Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in May 2018, Amneal Pharmaceuticals launched vigabatrin for oral solution USP, which is a generic equivalent for Sabril.

Infantile Spasm Market Key Companies to Watch

Mallinckrodt Pharmaceuticals

Company Overview: Mallinckrodt Pharmaceuticals is an American-Irish domiciled manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. It is founded in 1840. In 2017 it generated 90% of its sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S.

Product Portfolio: The Company's portfolio comprised of include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products.

Key developments: In April 2014, Mallinckrodt Pharmaceuticals acquired Questcor, a company involved in contract manufacturing services. Questcor has FDA-approved H.P. Acthar Gel, an injectable drug for 19 indications such as infantile spasm.

Why Purchase the Report?

  • Visualize the composition of the infantile spasm market segmentation by product type, route of administration, distribution channel and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in infantile spasm market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of infantile spasm market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global infantile spasm market report would provide an access to an approx. 61 market data table, 51 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Infantile Spasm Market - By Product Type

  • Adrenocorticotropic Hormone
  • Vigabatrin
  • Phase III

Global Infantile Spasm Market - By Route of Administration

  • Oral
  • Parenteral

Global Infantile Spasm Market - By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Infantile Spasm Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Infantile Spasm Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Infantile Spasm Market - Market Definition and Overview

3. Global Infantile Spasm Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Infantile Spasm Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing scientific advancements in the treatment for infantile spasms
      • 4.1.1.2. Rising prevalence of infantile spasms
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Infantile Spasm Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Infantile Spasm Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Infantile Spasm Market - By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Adrenocorticotropic Hormone*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Vigabatrin
  • 7.4. Phase III

8. Global Infantile Spasm Market - By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Parenteral

9. Global Infantile Spasm Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. Global Infantile Spasm Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Infantile Spasm Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Global Infantile Spasm Market- Company Profiles

  • 12.1. Mallinckrodt Pharmaceuticals*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Valerion Therapeutics
  • 12.3. Anavex Life Sciences Corp
  • 12.4. GW Pharmaceuticals, plc
  • 12.5. H. Lundbeck A/S
  • 12.6. ORPHELIA Pharma SA
  • 12.7. INSYS Therapeutics, Inc
  • 12.8. Retrophin, Inc
  • 12.9. Catalyst Pharmaceuticals
  • 12.10. Amneal Pharmaceuticals
  • 12.11. QUALITY CONTROL CHEMICALS INC
  • 12.12. BOC Sciences
  • 12.13. Chongqing Chemdad Co., Ltd
  • 12.14. Shanghai Longyu Biotechnology Co., Ltd
  • 12.15. Dayang Chemicals Co., Ltd.

LIST NOT EXHAUSTIVE

13. Global Infantile Spasm Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us